Stratagene Plans to Reabsorb Now-Independent Iobion Following Hycor Merger | GenomeWeb

Gene expression software firm Iobion, spun out of privately held Stratagene two years ago, will be folded back into the larger firm upon its merger with publicly traded Hycor, Stratagene said last week

Stratagene’s merger with diagnostic manufacturer Hycor is expected to close in the fourth quarter of 2003. The combined entity, to be named Stratagene, will trade on Nasdaq, generate combined revenues of over $85 million for 2003, and employ around 500 people. Hycor and Iobion will be wholly owned subsidiaries of Stratagene.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.